Discussion
toxicity, mCRPC
The results presented suggest NIRA + AAP has promising efficacy and a manageable toxicity profile in patients with mCRPC and alterations in genes associated with HRR who had progressed on 1 prior line of novel AR-targeted therapy. The current phase II study is limited by the open-label, single-arm trial design, and the small patient population. Whereas these findings are consistent with the BEDIVERE